Results 211 to 220 of about 41,600 (260)

Exercise or Fasting in Individuals With Type 2 Diabetes Receiving Once‐Weekly Basal Insulin Icodec

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8523-8532, September 2026.
ABSTRACT Aims To investigate glucose levels and hypoglycaemia risk during exercise or fasting in adults with type 2 diabetes (T2D) treated with once‐weekly basal insulin icodec. Materials and Methods Thirty basal insulin‐treated, physically active individuals with T2D (18–75 years, glycated haemoglobin ≤ 75 mmol/mol, peak oxygen uptake > 20 mL/kg/min ...
Thomas R. Pieber, Harpreet S. Bajaj, Gabriele Fluhr, Klara R. Klein, Thaís M. Pagliaro Rocha, Harald Sourij, Eva Svehlikova, Keerthana Udupa, Sara K. Watt, Maria Willerslev‐Olsen, Rasmus Ribel‐Madsen   +10 more
wiley   +1 more source

The Causal Mechanism Between the Dipeptidyl Peptidase-4, Heart Failure, and Other Cardiovascular Diseases: A Mendelian Randomization and Mediation Study. [PDF]

Int J Endocrinol
Chen CK, Kuo CF, Chang YJ, Zhang W, Doherty M, Chang ML, Chen TH.   +6 more
europepmc   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitor Use with COVID-19 Mortality in Diabetic Patients: A Nationwide Cohort Study in Korea. [PDF]

J Clin Med
Park JW, Kwak MK, Park S, Heo NH, Lee EY.   +4 more
europepmc   +1 more source

Dipeptidyl Peptidase 4 (DPP4) Exacerbates Osteoarthritis Progression in an Enzyme-Independent Manner. [PDF]

Adv Sci (Weinh)
Li X, Zhang Z, Jiang W, Ju Y, Guo W, Huang Z.   +5 more
europepmc   +1 more source

Synthetic Strategies for Activity‐Based Probes to Decode Ubiquitin‐Like Modifiers

Chemistry – A European Journal, Volume 32, Issue 30, 13 August 2026.
ABSTRACT Ubiquitin‐like proteins (Ubls) such as SUMO, NEDD8, ISG15, URM1, UFM1, FAT10, ATG8/ATG12, and FUBI are essential regulators of cellular homeostasis, controlling processes from protein stability and trafficking to immune signaling and autophagy.
Saibal Chanda, Alan Pham, SreeNidhi Karnati, Natalia Soto Rodriguez, Alyssa Toner, Wenshe Ray Liu   +5 more
wiley   +1 more source

PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer. [PDF]

Br J Cancer
Stange C, Dreyer TF, Riedel M, Elsen F, Seitz S, Hamann D, Kiechle M, Bronger H.   +7 more
europepmc   +1 more source

Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes. [PDF]

Diabetes Obes Metab
Sørensen KK, Yazdanfard PDW, Zareini B, Wood-Kurland HK, Pedersen-Bjergaard U, Andersen MP, Michelsen J, Imberg H, Lind M, Hallström S, Lanzinger S, Munch A, Ohlendorff JS, Gerds TA, Torp-Pedersen C, REDDIE Consortium.   +15 more
europepmc   +1 more source

Real‐World Effectiveness and Safety of iGlarLixi in People With Type 2 Diabetes in LATAM Region: A Subanalysis of the SUCCESS Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8724-8728, September 2026.
Juan Manuel Arteaga‐Diaz, Jose Luis Torres‐Grajales, Leobardo Sauque‐Reyna, Carlos Salamanca‐Carrillo, Luis Anguiano‐Medrano   +4 more
wiley   +1 more source

Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes. [PDF]

J Intern Med
Hung TY, Lin TC, Liou YJ, Lin TH, Hsu YJ, Lin LY, Wang MT.   +6 more
europepmc   +1 more source